SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...
Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized ...
Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma. This is an ASCO Meeting Abstract from the 2016 ASCO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results